In continuation to our earlier invitation and subsequent reminders to submit abstracts for the upcoming APASL Single Theme Conference on HCV Infection and Diseases, scheduled for December 2015 in New Delhi, this is, yet again, an urgent reminder for submission of your abstract by September 15, 2015 positively.
Your timely submission of the abstract will ensure the release of the supplement of the abstracts for distribution at the time of the conference.
Kindly adhere to the guidelines and the deadline of abstract submission strictly by September 15, 2015.
*** Registration and Abstract Submission now Available! ***
Deadline for submission of abstracts: September 30, 2015
Close of early bird registration: November 30, 2015
Please Register by November 30, 2015 to take advantage of reduced fees! We look forward to welcoming you in Tokyo in February 2016.
Feb 20 (Saturday) 2016 : Post Graduate Course
Feb 21 (Sunday) 2016 : Opening Ceremony / HCV Day
Feb 22 (Monday) 2016 : HBV Day
Feb 23 (Tuesday) 2016 : HCC / NASH Day
Feb 24 (Wednesday) 2016: NASH / Other Day / Closing Ceremony
For more information, please visit APASL 2016 Website at
Please also check the latest news of APASL 2016 through the SNSs of APASL 2016 at following pages.
The venue has easy access to both Narita and Haneda Tokyo International Airports.
Also it is only a few minutes walking distance from Shinagawa Station, the terminal station of the Shinkansen bullet train. There are various accommodation options with different categories and price ranges around the venue.
Japanese Tradition in Tokyo.
Tokyo Metropolitan Government will offer the “Complimentary Hospitality Program” for the overseas delegates of APASL 2016. The cultural programs conducted in English gives you an opportunity to feel Japanese traditions. The programs are offered as complimentary basis for participants of APASL2016 and you can book these programs onsite* at the venue. More details will be coming soon at APASL2016 Website!
* Because the participation number of this program is limited, application will be closed as soon as it fills up.
Our Journal is Now on Medline!!
||Our Journal is Now on Medline! And available to all APASL members!!
Dear APASL member
It is a matter of great satisfaction and joy to inform that the Hepatology International has been recently accepted by Medline for indexing, and all the papers published so far are now cited on PubMed. This has been a long standing requirement of the APASL members and the academic community of this journal, which has been fulfilled now.
Please log into the member site of APASL https://apasl.info/member/ with your ID and Password, and reach the journal content through the hyperlink.
Prof. Shiv K Sarin / Prof. Masao Omata,
Chief in Editor, Hepatology International
Contact: APASL Secretariat-Tokyo
Asian Pacific Association for the Study of the Liver [APASL]
Tel: +81-3-5312-7686 Fax: +81-3-5312-7687
The following guidelines are now free access on the journal website!
Vol 8; issue 4, October 2014 (http://link.springer.com/journal/12072/8/4/page/1)
Guidelines: Acute-on-chronic liver failure:
consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Shiv Kumar Sarin, Chandan Kumar Kedarisetty, Zaigham Abbas…
World Hepatitis Day 2015
***** Report from Turkey *****
“Hepatitis C Myths are Contagious” Project and surveys conducted within the scope of the World Hepatitis Day activities reveal myths about Hepatitis C, which is a significant public health issue.
“Hepatitis C Myths are Contagious” Project aims to correct prejudices and myths about hepatitis C in public and help to understand causes of stigmatization among patients, their families, society, and even healthcare professionals.
Istanbul, 24 July 2015- The dramatic results of the survey within the scope of “Hepatitis C Myths are Contagious” Project have been announced in a press meeting organized in İstanbul on 24 July within the scope of World Hepatitis Week activities.
There are 170 million people worldwide with chronic hepatitis.1 Each year more than 350,000 people lose their lives because of Hepatitis C, and 3% of the global population carry Hepatitis C virus.2,3
Besides being a significant public health issue, myths and incomplete information about the disease is also a significant cause for stigmatization. The general perception is that the disease is transmitted only through sexual means or drug abuse. The resulting stigmatization has a significant impact on patients’ social and business lives, and from time to time may even cause problems in getting support from healthcare professionals.4 Hepatitis C is in fact an infectious disease and the general misinformation about this disease is more contagious than hepatitis C itself, which is mostly blood borne.
The “Hepatitis C Myths are Contagious” Task Force, established with the participation of the Society for Fight Against Viral Hepatitis, Turkish Association for the Study of the Liver, Turkish Gastroenterology Society, Turkish Society for Infectious Diseases and Clinical Microbiology Specialty, the Hepato-Bilio-Pancreatology Association (HEBIPA), Turkish Liver Foundation and Living with Hepatitis Patient Association Hep Yaşam; and the contribution of global biopharma company AbbVie aims to increase awareness in society, patients, families, and healthcare professionals; and support prevention of stigmatization through correcting the prejudices and misperceptions that result from being insufficiently informed about Hepatitis C.
The first step in the project was to make in-depth interviews with patients and their families as well as healthcare professionals to collect data about the perception of Hepatitis C.
Patients experience problems such as lack of trust, loss of self-esteem and anxiety due to issues during the diagnosis process.
Following in-depth interviews and a focus group study, it is demonstrated that patients and their relatives do not have any information about hepatitis C before the diagnosis. When the diagnosis is announced without giving adequate information about the disease, patients feel panic, uncertainty, fear of stigmatization and hopelessness; which hinder the motivation to fight against the disease. Survey also shows that in some cases patients are divorced, deserted, or stigmatized by their neighbors, colleagues and healthcare professionals after diagnosis; which all lead to problems such as loss of trust, loss of self-esteem, and anxiety among patients. Within this context, not being informed enough or being misinformed lead to psychological and social problems for the patients and their families. Patients get the information about the disease mostly from their physicians, but the work burden on healthcare professionals prevent them giving comprehensive information on the subject. Consequently, patients and their families do not have any information about Hepatitis C unless there’s already another patient around them.5
Survey conducted among healthcare professionals shows that just like the public, healthcare professionals also do not have accurate and adequate information on Hepatitis C.
Data from the focus group conducted with healthcare professionals demonstrate that most of participants believe that Hepatitis C is an incurable disease with a negative course. The most dramatic results from survey show that Hepatitis C patients are put at the end of the waiting list for operations because of the risk of transmission, some nurses avoid assisting in their operations, and some dentists refrain from treating Hepatitis C patients. Survey also demonstrates that healthcare providers in other specialties do not have enough information about Hepatitis C; furthermore, routine precautions for preventing transmission are not taken during physical examinations in first-line settings or procedures such as drawing blood/making injections. All these data show that the public, the patients and even healthcare professionals do not have accurate and adequate information about Hepatitis C.5
The “Hepatitis C Myths are Contagious Task Force”, who shared the data they have so far collected with the public on the occasion of 28 July World Hepatitis Day, next plan to undertake projects to inform the society and healthcare professionals in the light of these data.
Prof. A.Kadir Dokmeci- Immediate Past President of APASL, Member of SC/EC
Prof. Necati Ormeci - Member of EC
APASL Future Meetings
We APASL will hold following conferences in the future!
APASL STC on HBV in Armenia
APASL STC on HCV in India
Date: December 18-20, 2015
City: New Delhi, India
Conference Patron: Dr. S K Sarin
Conference Chairman: Dr. B C Sharma
Conference Secretary: Dr. Manoj Kumar
APASL STC on Cirrhotic Complications in Korea
Date: April 8-10, 2016
City: Busan, Korea
Venue: Paradise Hotel Busan
President: Dr. Kwang-Hyub Han
APASL STC on HCV in Taiwan
Date: June 10-12, 2016
City: Kaohsiung, Taiwan
Venue: Kaohsiung Exhibition Center
President: Dr. Wan-Long Chuang
It is our pleasure to inform you that we have elected a 2015 fellow successfully and now we are in preparation phase to offer the fellow the best placement for pursuing his career.
The objective of the fellowship is to foster career development by encouraging the beneficial experience of working in a different clinical or research environment in another country in the Asia-Pacific region. These fellowships provide for advanced training in health and medical research in any country in the Asia-Pacific region and enable fellows to work in a clinical environment or on a research project with nominated advisers. We appreciate your generous contributions and support for these APASL fellowships and look forward to a number of high-quality applications for a 2016 fellowship.
There are no restrictions based on nationality. The sponsoring institution with the academic environment to provide adequate support for the proposed project might be suggested by APASL. Application will be reviewed by APASL Committee members. The decisions of the Committee are final and not subject to appeal.